Table I.
Association between pERK expression at the invasive front and clinicopathological characteristics of HCM patients.
| pERK status | |||
|---|---|---|---|
|
|
|||
| Characteristic | Positive (n=7) | Negative (n=15) | P-value |
| Age, n (%) | |||
| ≥61 years | 4 (57.1) | 6 (40.0) | 0.652 |
| <61 years | 3 (42.9) | 9 (60.0) | |
| Gender, n (%) | |||
| Male | 5 (71.4) | 10 (66.7) | 1.000 |
| Female | 2 (28.6) | 5 (33.3) | |
| HCM, n (%) | |||
| Single | 4 (57.1) | 11 (73.3) | 0.630 |
| Multiple | 3 (42.9) | 4 (26.7) | |
| HCM size, n (%) | |||
| ≥2.5 cm | 3 (42.9) | 8 (53.3) | 1.000 |
| <2.5 cm | 4 (57.1) | 7 (46.7) | |
| HCM distribution, n (%) | |||
| Unilobar | 6 (85.7) | 12 (80.0) | 1.000 |
| Bilobar | 1 (14.3) | 3 (20.0) | |
| HCM recurrence, n (%) | |||
| Present | 7 (100.0) | 1 (6.7) | <0.001a |
| Absent | 0 (0.0) | 14 (93.3) | |
| Median survival (range), monthsb | 26 (1–62) | 28 (6–85) | 0.853 |
a
Statistically significant.
pERK, phosphorylated extracellular signal-regulated kinase; HCM, hepatic colorectal metastasis.